Previous 10 | Next 10 |
Instil Bio has filed terms for its $250 million IPO. The firm is advancing autologous TIL treatment candidates for melanoma and other solid tumor cancers. TIL has produced intriguing early efficacy results but the IPO is priced far above the normal life science IPO range, so I'll ...
Immatics is a very early-stage biotech company with most assets still in the pre-clinical phase. They have a proprietary oncology platform that generates T cell targets against Cancer-Testis Antigens. Despite being exceptionally early in development, Immatics already has establish...
SAN CARLOS, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that long-term interim data from Cohort 2 in the C-144-01 clinical study (NCT02360579...
The following slide deck was published by Iovance Biotherapeutics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Iovance Biotherapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
Iovance Biotherapeutics, Inc. (IOVA) Q4 2020 Earnings Conference Call February 25, 2021 16:30 ET Company Participants Maria Fardis - Chief Executive Officer & President Friedrich Finckenstein - Chief Medical Officer Jean Marc Bellemin - Chief Financial Officer Sara Pellegrino - Vice Presi...
Iovance (IOVA) shares had a rough day, closing down 7.3% to $36.54 before its Q4 2020 results were released.Those results showed the company missed on EPS.The company did not report any revenues in either Q4 2020 or Q4 2019.Iovance's net loss quarter over quarter widened slightly fr...
SAN CARLOS, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported fourth quart...
SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. Ma...
NexImmune has filed to raise $75 million from an IPO of its common stock. The firm is advancing nanoparticle-assisted treatment candidates for various blood and other cancers. Barclays is the lead underwriter and its IPOs have performed in the middle tier over the last 12 months. ...
Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020 compared to the 16% in the SPDR S&P 500 Trust ETF (SPY). The outlook is underpinned by uncertainty...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL recommendation for IOVA on July 29, 2024 02:11AM ET. The previous analyst recommendation was Overweight. IOVA was trading at $9.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-29 05:00:08 ET Joseph Catanzaro from Piper Sandler issued a price target of $10.00 for IOVA on 2024-07-29 02:11:00. The adjusted price target was set to $10.00. At the time of the announcement, IOVA was trading at $9.25. The overall price target consensus is at $...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...